title: Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?
abstract: Factor H binding protein (fHbp) is a principal antigen in a multicomponent meningococcal vaccine recently licensed in Europe for prevention of serogroup B diseases. The protein recruits the complement downregulator, factor H (fH), to the bacterial surface, which enables the organism to resist complement-mediated bacteriolysis. Binding is specific for human fH. In preclinical studies, mice and rabbits immunized with fHbp vaccines developed serum bactericidal antibody responses, which in humans predict protection against developing meningococcal disease. These studies, however, were in animals whose fH did not bind to the vaccine antigen. Here we review the immunogenicity of fHbp vaccines in human fH transgenic mice. The data suggest that animals with high serum human fH concentrations have impaired protective antibody responses. Further, mutant fHbp vaccines with single amino acid substitutions that decrease fH binding are superior immunogens, possibly by unmasking epitopes in the fH binding site that are important for eliciting serum bactericidal antibody responses. Humans immunized with fHbp vaccines develop serum bactericidal antibody, but achieving broad coverage in infants required incorporation of additional antigens, including outer membrane vesicles, which increased rates of fever and local reactions at the injection site. The experimental results in transgenic mice predict that fHbp immunogenicity can be improved in humans by using mutant fHbp vaccines with decreased fH binding. These results have important public health implications for developing improved fHbp vaccines for control of serogroup B meningococcal disease and for development of vaccines against other microbes that bind host molecules.
authors.affiliation: Center for Immunobiology and Vaccine Development, Children's Hospital Oakland Research Institute, Oakland, CA, USA. dgranoff@chori.org
authors.forename: Dan M
authors.initials: DM
authors.lastname: Granoff
authors.forename: Sanjay
authors.initials: S
authors.lastname: Ram
authors.forename: Peter T
authors.initials: PT
authors.lastname: Beernink
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology*; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D001426:Bacterial Proteins / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D001770:Blood Bactericidal Activity; D017242:Complement Factor H / Q000276:immunology / Q000378:metabolism; D006801:Humans; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D008822:Mice, Transgenic; D050505:Mutant Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D009345:Neisseria meningitidis / Q000276:immunology*; D011485:Protein Binding
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C493495:CFH protein, human; D022401:Meningococcal Vaccines; D050505:Mutant Proteins; C484699:factor H-binding protein, Neisseria meningitidis; D017242:Complement Factor H